目的： 总结免疫检查点抑制剂（ICIs）在肝胆肿瘤治疗中出现的不良反应，提供实用的护理对策。方法： 纳入东南大学附属中大医院2020年1月至2021年1月经确诊并使用ICIs治疗的恶性肝胆肿瘤患者，根据是否施加护理干预将其分为护理干预组和非干预组，比较两组患者并发症、用药周期和护理满意情况。结果： 最终共纳入53例，其中护理干预组27例，非干预组26例。护理干预组中位用药周期长于非干预组，差异具有统计学意义（χ²=4.39，P=0.036）。同时，护理干预组医疗满意度评分高于非干预组，差异具有统计学意义（χ²=4.92，P=0.027）。但两组的免疫相关不良反应比较差异无统计学意义（P>0.05）。结论： ICIs治疗恶性肝胆肿瘤总体安全性较好，通过护理干预，患者的用药周期和满意度均显著提升。

[1] MARIN-ACEVEDO J A,DHOLARIA B,SOYANO A E,et al.Next generation of immune checkpoint therapy in cancer:new developments and challenges[J].J Hematol Oncol,2018,11(1):39-59.
[2] FINN R S,QIN S,IKEDA M,et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J].N Engl J Med,2020,382(20):1894-1905.
[3] KLEIN O,KEE D,NAGRIAL A,et al.Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers:subgroup analysis of a phase 2 nonrandomized clinical trial[J].JAMA Oncol,2020,6(9):1405-1409.
[4] BOILEVE A,HILMI M,SMOLENSCHI C,et al.Immunotherapy in advanced biliary tract cancers[J].Cancers(Basel),2021,13(7):1569-1587.
[5] BINIAKEWITZ M D,KASLER M K,FESSELE K L.Immune-related adverse events in the older adult with cancer receiving immune checkpoint inhibitor therapy[J].Asia Pac J Oncol Nurs,2021,8(1):18-24.
[6] U.S.Department of Health and Human Services,National Institutes of Health,National Cancer Institut.Common Terminology Criteria for Adverse Events.[EB/OL]v 5.0.2017.https://www.eortc.be/services/doc/ctc/CTCAE_v5_Quick.
[7] TANG S Q,TANG L L,MAO Y P,et al.The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in iancer:a pooled analysis of 23 clinical trials and 8,436 patients[J].Cancer Res Treat,2021,53(2):339-354.